Monographs Not Viable for Unapproved Prescription Drug Review, FDA Says
Executive Summary
A monograph system is not a viable approach for evaluating the safety and efficacy of prescription drugs that are marketed without FDA approval, agency officials told an overflow crowd during a Jan. 9 workshop on unapproved drugs
You may also be interested in...
Counterfeit Drugs, Food Safety Are Expected Focus Of New FDA Bill In House
Tightened security for counterfeit drugs and food imports are slated to be addressed in another bill aimed at boosting FDA's oversight powers, Energy and Commerce Committee Chairman John Dingell, D-Mich., said during markup of drug safety legislation
Counterfeit Drugs, Food Safety Are Expected Focus Of New FDA Bill In House
Tightened security for counterfeit drugs and food imports are slated to be addressed in another bill aimed at boosting FDA's oversight powers, Energy and Commerce Committee Chairman John Dingell, D-Mich., said during markup of drug safety legislation
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval